![]() |
市场调查报告书
商品编码
1941278
神经科学市场报告:按组件、技术、最终用户和地区划分(2026-2034 年)Neuroscience Market Report by Component, Technology, End User, and Region 2026-2034 |
||||||
2025年全球神经科学市场规模为371亿美元。展望未来,IMARC集团预测,到2034年,该市场规模将达到486亿美元,2026年至2034年的复合年增长率(CAGR)为3.07%。推动市场成长的关键因素包括:神经系统疾病盛行率上升、研发投入增加、神经影像工具技术进步、人们对心理健康问题的认识不断提高、神经资讯学和义肢领域的应用不断扩展、人口快速老化以及政府的支持政策。
神经系统疾病呈上升趋势
在全球范围内,阿兹海默症、帕金森氏症和癫痫等神经系统疾病的日益增多,是推动神经科学市场成长的主要因素。目前,美国约有700万人患有阿兹海默症,预计到2050年,这一数字将几乎翻倍。这一增长主要归因于人口老化加剧,老年人更容易患有神经退化性疾病。因此,对先进诊断工具和有效治疗策略的需求日益增长,这促使人们研究这些疾病背后的生物学机制,以期开发出更具针对性和更有效的治疗方法。人工智慧驱动的诊断系统,例如2023年推出的飞利浦CT 3500,体现了设备领域的快速技术创新,并提高了神经系统评估的准确性和速度。此外,因神经系统疾病住院人数的增加以及医疗基础设施的不断完善,也推动了对先进诊断和治疗解决方案的需求,预计医院行业将实现最快的增长。
加大对神经科学研发的投入
神经科学领域正经历来自公共和私人机构的资金激增。这些投资支持广泛的研究工作,从基础脑科学研究到脑图谱绘製和神经数据整合等尖端技术的发展。政府机构和慈善组织特别关注对大脑功能及其障碍的理解,而私人企业(特别是生物技术和製药领域的企业)则致力于新药和新治疗方法的研发。这些投资也促进了医疗耗材产业的发展,例如贝朗公司(B. Braun SE)和通用电气医疗集团(GE Healthcare)等公司提供的耐用、易用的产品,如患者监护仪和注射器,提高了神经科护理的效率。这些资金支持正在加速科学发现的步伐,并有助于将研究成果转化为实际的临床应用。
神经影像工具的技术进步
近年来,包括磁振造影(MRI)、正影像处理速度和更精确的数据分析。这使得早期发现脑部异常和更精确地定位病灶成为可能,而这对于制定有效的治疗方案至关重要。此外,神经显微镜技术正迅速发展成为一个革命性的领域,由丹纳赫公司和卡尔蔡司公司等企业开发的超小型电子显微镜不仅有助于检测神经损伤,而且有望促进其修復。这些创新正在拓展临床医生和研究人员的能力,使神经影像学成为现代神经科学的重要组成部分。
The global neuroscience market size reached USD 37.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 48.6 Billion by 2034, exhibiting a growth rate (CAGR) of 3.07% during 2026-2034. Increasing prevalence of neurological disorders, rising investment in research and development (R&D), technological advancements in neuroimaging tools, growing awareness of mental health issues, expanding applications in neuroinformatics and neuroprosthetics, burgeoning aging populations, and supportive government policies are some of the factors facilitating the market growth.
Increasing Prevalence of Neurological Disorders
The global rise in neurological conditions such as Alzheimer's disease, Parkinson's disease, and epilepsy is a major factor driving the growth of the neuroscience market. In the United States, Alzheimer's currently affects around 7 million people, and this number is projected to nearly double by 2050. This increase is largely due to the aging population, which is more prone to neurodegenerative diseases. As a result, there is a growing demand for advanced diagnostic tools and effective treatment strategies. This has led to intensified research into the biological mechanisms underlying these disorders, with the goal of developing more targeted and effective therapies. The introduction of AI-powered diagnostic systems, such as the Philips CT 3500 launched in 2023, reflects the rapid innovation in the instrument segment, enhancing the precision and speed of neurological assessments. Moreover, the hospital sector is expected to witness the fastest growth, fueled by a rise in neurological admissions and the expansion of healthcare infrastructure, which is increasing the demand for sophisticated diagnostic and therapeutic solutions.
Rising Investment in Neuroscience Research and Development
The neuroscience field is experiencing a surge in funding from both public institutions and private enterprises. These investments support a wide range of initiatives, from fundamental brain research to the development of advanced technologies, such as brain mapping and neural data integration. Government agencies and philanthropic organizations are particularly focused on understanding brain function and dysfunction, while private companies-especially in the biotech and pharmaceutical sectors-are investing in the development of new drugs and therapies. These investments are also strengthening the consumables segment, with companies such as B. Braun SE and GE Healthcare offering durable, user-friendly products like patient monitors and injectors that enhance the efficiency of neurological care. This financial support is accelerating the pace of scientific discovery and helping to translate research findings into practical clinical applications.
Technological Advancements in Neuroimaging Tools
Recent advancements in neuroimaging technologies-including MRI, PET, and EEG-have significantly improved the diagnosis and monitoring of neurological disorders. These tools now offer higher resolution, faster imaging speeds, and more accurate data analysis through advanced algorithms. This has enabled earlier detection of brain abnormalities and more precise localization of lesions, which is critical for effective treatment planning. Additionally, neuro-microscopy is emerging as a transformative area, with companies like Danaher Corporation and Carl Zeiss AG developing ultra-miniature electronic microscopes that can not only detect but may also help reverse neurological damage. These innovations are expanding the capabilities of clinicians and researchers, making neuroimaging an essential component of modern neuroscience.
Instruments and consumables accounts for the majority of the market share
The instruments and consumables segment is driven by the increasing demand for advanced diagnostic and surgical tools in medical and research settings. Technological advancements such as precision instruments and high-throughput consumables are enhancing efficiency and accuracy in diagnostics and experimental procedures, thereby boosting market growth. Moreover, expanding applications in genomic and proteomic research are driving the need for specialized instruments and consumables tailored for molecular analysis and sample preparation. Furthermore, the segment benefits from rising healthcare expenditure globally, which supports investments in state-of-the-art equipment and disposable consumables that ensure patient safety and procedural efficacy. Additionally, regulatory developments mandating the use of certified instruments and sterile consumables in healthcare facilities are influencing market dynamics, encouraging manufacturers to innovate and comply with stringent quality standards.
Brain imaging accounts for the majority of the market share
The brain imaging segment is driven by the increasing demand for advanced diagnostic capabilities in neurological disorders. With conditions such as Alzheimer's disease, Parkinson's disease, and strokes on the rise globally, there is a growing need for accurate and early detection methods to facilitate prompt treatment and management. Technological advancements in imaging modalities like magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) have significantly enhanced resolution, speed, and sensitivity, allowing for detailed visualization of brain structures and functions. These advancements not only enable clinicians to pinpoint abnormalities and track disease progression more effectively but also support the development of personalized treatment plans tailored to individual patient needs. Apart from this, the integration of artificial intelligence (AI) and machine learning (ML) algorithms into brain imaging technologies has further bolstered diagnostic accuracy and efficiency, driving adoption across clinical and research settings.
The hospitals segment is driven by the increasing demand for specialized healthcare services, advanced medical technologies, and comprehensive patient care. Hospitals are expanding their facilities and services to cater to growing populations and rising healthcare needs, including surgical procedures, emergency care, and chronic disease management. Additionally, advancements in medical treatments and therapies, coupled with the integration of digital health technologies, are enhancing hospital efficiency and patient outcomes. Collaborations with pharmaceutical companies and research institutions further drive innovation in medical treatments and diagnostic capabilities within hospital settings.
The diagnostic laboratories segment is driven by the increasing prevalence of diseases requiring early and accurate diagnosis, such as cancer, cardiovascular disorders, and infectious diseases. Diagnostic labs play a crucial role in disease detection, monitoring, and treatment planning, leveraging advanced diagnostic technologies like molecular diagnostics, next-generation sequencing, and advanced imaging techniques. Moreover, the shift towards personalized medicine and precision diagnostics is driving demand for specialized tests and biomarker analysis, contributing to the growth of diagnostic laboratories worldwide. Collaborations with healthcare providers and research institutes enhance the development and adoption of innovative diagnostic solutions.
The research and academic institutes segment is driven by the expanding scope of scientific research across various disciplines, including medicine, biotechnology, and neuroscience. These institutes contribute significantly to advancements in healthcare through fundamental research, clinical trials, and translational research aimed at developing new therapies, drugs, and medical devices. Funding from government grants, private foundations, and collaborations with pharmaceutical companies supports research initiatives and infrastructure development in academic institutions. Additionally, partnerships with hospitals and diagnostic laboratories facilitate knowledge exchange and the application of research findings in clinical practice, driving innovation and improving patient care globally.
Other healthcare segments, such as clinics and ambulatory surgical centers, are driven by the increasing demand for outpatient services, convenience, and cost-effective healthcare delivery models. These facilities offer specialized medical services, preventive care, and minor surgical procedures outside traditional hospital settings. The rise of chronic diseases, aging populations, and healthcare reforms emphasizing preventive care and outpatient treatments are fueling the growth of clinics and ambulatory centers.
North America leads the market, accounting for the largest neuroscience market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The North America regional market is driven by the increasing prevalence of chronic diseases such as cardiovascular diseases, diabetes, and obesity, which have heightened demand for advanced healthcare solutions and medical devices. This dominance is largely due to the significant presence of companies focused on developing, manufacturing, and commercializing devices for diagnosing and treating neurological conditions. For example, in February 2022, CERENOVUS introduced the EMBOGUARD, an advanced balloon guide catheter designed for use in endovascular procedures, particularly for patients with acute ischemic stroke. The Asia Pacific region is projected to experience the fastest growth in the coming years. This growth is fueled by increasing investments in healthcare infrastructure and high levels of healthcare spending, which are driving the expansion of the neuroscience industry. A notable example is China's "China Brain Project" (CBP), launched in September 2022 with an initial investment of USD 746 Million. The project aims to explore the neural basis of cognitive functions, brain-inspired computing, and advancements in diagnosing and treating brain disorders. Such government initiatives are expected to accelerate research and development in neuroscience, further boosting market growth.